PROVAYBLUE- methylene blue
American Regent, Inc.
PROVAYBLUE ® may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs. Avoid concomitant use of PROVAYBLUE ® with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors ( 5.1, 7.1). [see Warnings and Precautions ( 5.1) and Drug Interactions ( 7.1)]
PROVAYBLUE ® USP is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials [ see Clinical Studies ( 14.1) ].
- Ensure patent venous access prior to administration of PROVAYBLUE®. Do not administer PROVAYBLUE® subcutaneously.
- Monitor vital signs, electrocardiogram and methemoglobin levels during treatment with PROVAYBLUE® and through resolution of methemoglobinemia.
- Administer PROVAYBLUE® 1 mg/kg intravenously over 5-30 minutes.
- If the methemoglobin level remains greater than 30% or if clinical signs and symptoms persist, a repeat dose of PROVAYBLUE® 1 mg/kg may be given one hour after the first dose.
- If methemoglobinemia does not resolve after 2 doses of PROVAYBLUE®, consider initiating alternative interventions for treatment of methemoglobinemia.
- The recommended dosage of PROVAYBLUE in patients with moderate or severe renal impairment (eGFR 15-59 mL/min/1.73 m2) is a single dose of 1 mg/kg.
- If the methemoglobin level remains greater than 30% or if the clinical symptoms persist 1 hour after dosing, consider initiating alternative interventions for the treatment of methemoglobinemia.
Each mL of PROVAYBLUE ® contains 5 mg methylene blue
Each 10 mL ampule of PROVAYBLUE ® contains 50 mg methylene blue. Each 2 mL ampule of PROVAYBLUE® contains 10 mg methylene blue.
PROVAYBLUE ® is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose in Water (D5W) in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.
Avoid diluting with sodium chloride solutions, because it has been demonstrated that chloride reduces the solubility of methylene blue.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Keep the ampule in the original package to protect from light.
Injection: 50 mg/10 mL (5 mg/mL) or 10 mg/2 mL (5 mg/mL) clear dark blue solution in single-dose ampules.
PROVAYBLUE ® is contraindicated in the following conditions:
- Severe hypersensitivity reactions to methylene blue or any other thiazine dye [see Warnings and Precautions ( 5.2)] .
- Patients with glucose-6-phosphate dehydrogenase deficiency (G6PD) due to the risk of hemolytic anemia [see Warnings and Precautions ( 5.3, 5.4)]
The development of serotonin syndrome has been reported with use of methylene blue class products. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors). Some of the reported cases were fatal. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, and hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, and incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Avoid concomitant use of PROVAYBLUE ® with serotonergic drugs.
Patients treated with PROVAYBLUE ® should be monitored for the emergence of serotonin syndrome. If symptoms of serotonin syndrome occur, discontinue use of PROVAYBLUE ® , and initiate supportive treatment. Inform patients of the increased risk of serotonin syndrome and advise them to not to take serotonergic drugs within 72 hours after the last dose of PROVAYBLUE ® [see Drug Interactions ( 7), Patient Counseling Information ( 17)] .
Anaphylactic reactions to methylene blue class products have been reported. Patients treated with PROVAYBLUE ® should be monitored for anaphylaxis. If anaphylaxis or other severe hypersensitivity reactions (e.g., angioedema, urticaria, bronchospasm) should occur, discontinue use of PROVAYBLUE ® and initiate supportive treatment. PROVAYBLUE ® is contraindicated in patients who have experienced anaphylaxis or other severe hypersensitivity reactions to a methylene blue class product in the past.
Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE ® in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. Monitor response to therapy with PROVAYBLUE ® through resolution of methemoglobinemia. If methemoglobinemia does not respond to 2 doses of PROVAYBLUE ® or if methemoglobinemia rebounds after a response, consider additional treatment options [see Dosage and Administration ( 2.2)] .
Patients with glucose-6-phosphate dehydrogenase deficiency may not reduce PROVAYBLUE ® to its active form in vivo. PROVAYBLUE ® may not be effective in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Hemolysis can occur during treatment of methemoglobinemia with PROVAYBLUE ®. Laboratory testing may show Heinz bodies, elevated indirect bilirubin and low haptoglobin, but the Coombs test is negative. The onset of anemia may be delayed 1 or more days after treatment with PROVAYBLUE ®. The anemia may require red blood cell transfusions [see Adverse Reactions ( 6.1)]. Use the lowest effective number of doses of PROVAYBLUE ® to treat methemoglobinemia. Discontinue PROVAYBLUE ® and consider alternative treatments of methemoglobinemia if severe hemolysis occurs.
Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with PROVAYBLUE ® may result in severe hemolysis and severe anemia. PROVAYBLUE ® is contraindicated for use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency [see Contraindications ( 4)].
- Inaccurate Pulse Oximeter Readings
The presence of methylene blue in the blood may result in an underestimation of the oxygen saturation reading by pulse oximetry. If a measure of oxygen saturation is required during or shortly after infusion of PROVAYBLUE ® , it is advisable to obtain an arterial blood sample for testing by an alternative method.
- Bispectral index monitor
A fall in the Bispectral Index (BIS) has been reported following administration of methylene blue class products. If PROVAYBLUE ® is administered during surgery, alternative methods for assessing the depth of anesthesia should be employed.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.